Systemic Lupus ErythematosusPhase 1NCT02321709
Multiple Ascending Dose Study To Assess The Safety Profile Of SAR113244 Versus Placebo In Lupus Male And Female Patients
A Phase 1 study testing SAR113244 in people with Systemic Lupus Erythematosus, run by Sanofi at 1 site in Germany.
Trial summary
Primary Objective: To assess the tolerability and safety of SAR113244 in male and female lupus patients after every 4 (Q4) weeks repeated ascending subcutaneous doses of SAR113244. Secondary Objectives: To assess in male and female lupus patients: The pharmacokinetics of SAR113244. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Systemic Lupus Erythematosus
- What is being tested?
- SAR113244
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 21 participants
- Where
- 1 siteGermany
- Study dates
- Nov 2014to Mar 2016
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male or female patients, between 18 and 75 years of age, inclusive.
- Clinical diagnosis of systemic lupus erythematosus (SLE) by American College Rheumatology criteria.
- Autoantibody-posititve.
- On active and stable SLE disease.
Who cannot join
- Pregnant and nursing.
- Have received treatment with investigational drugs in the 4 months prior to the screening or 5 half-lives of the drug, whichever is longer.
- Have received intravenous or oral cyclophosphamide within 180 days of Day 0. Severe active lupus nephritis or chronic renal insufficiency.
- Active or chronic, severe neuropsychiatric lupus.
- Acute, recent (within 4 weeks of screening), chronic or frequently recurring infection(s), except minor infection.
- Have current drug or alcohol abuse or dependence.
- Have a historically positive test or test postitive at screening for HIV, hepatitis B, or hepatitis C.
- The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Randomized, Double-blind, Placebo-controlled Study Of Safety, Tolerability, And Pharmacokinetics Of Repeated Ascending Subcutaneous Doses Of SAR113244 And Pharmacodynamics Of Single Dose Of SAR113244 In Male And Female Lupus Patients
Primary Objective:
To assess the tolerability and safety of SAR113244 in male and female lupus patients after every 4 (Q4) weeks repeated ascending subcutaneous doses of SAR113244.
Read more
Secondary Objectives:
To assess in male and female lupus patients:
- The pharmacokinetics of SAR113244.
- The pharmacodynamics of SAR113244 for the following disease-related parameters:
- Safety of Estrogens in Lupus Erythematosus National Assessment - Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score, British Isles Lupus Assessment Group (BILAG) score (if applicable), BILAG-Based Composite Lupus Assessment (BICLA) (if applicable), systemic lupus erythematosus responder index (SRI) (if applicable), Lupus-quality of life (QoL) and Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue, anti-double stranded deoxyribonucleic acid antibody (anti-dsDNA Ab) and anti-nuclear antibody levels (ANA) and plasma complement levels (C3, C4), erythrocyte sedimentation (SED) rate and C-reactive protein.
- Peripheral blood B and T cells subsets.
Read the detailed description
The total duration of screening to end of study per subject is 20 weeks with post-study observation on Day 226 for anti-drug antibody assessment (for patients with positive anti-drug antibody at end of study only).
- Conditions
- Systemic Lupus Erythematosus
- Being tested
- SAR113244, placebo
- Medical subject headings
- Lupus Erythematosus, Systemic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SAR113244Drug
Pharmaceutical form:solution for injection Route of administration: subcutaneous
placeboDrug
Pharmaceutical form:solution for injection Route of administration: subcutaneous
| Study group | Role | What they receive |
|---|---|---|
| SAR113244 cohort 1 | Experimental | Two administrations of dosage 1 SAR113244 or placebo subcutaneous dose (Q4 weeks) Receives: Drug: SAR113244; Drug: placebo |
| SAR113244 cohort 2 | Experimental | Two administrations of dosage 2 SAR113244 or placebo subcutaneous dose (Q4 weeks) Receives: Drug: SAR113244; Drug: placebo |
| SAR113244 cohort 3 | Experimental | Two administrations of dosage 3 SAR113244 or placebo subcutaneous dose (Q4 weeks) Receives: Drug: SAR113244; Drug: placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of participants with adverse events and treatment-emergent adverse events
Measured: Up to 16 weeks after inclusion
Change in physical examination, body weight, vital signs and laboratory parameters
Measured: Up to 16 weeks after inclusion
Safety and tolerability (erythema, swelling, degree of itching, and present pain intensity at injection site by measuring diameter and qualitative assessment)
Measured: Up to 16 weeks after inclusion
Secondary outcomes (10)
Assessment of pharmacokinetic parameter - maximum concentration (Cmax)
Measured: Up to D113 after inclusion
Assessment of pharmacokinetic parameter - time of maximum concentration (Tmax)
Measured: Up to D113 after inclusion
Assessment of pharmacokinetic parameter - area under curve 0-4 weeks (AUC0-4w)
Measured: Up to D113 after inclusion
Assessment of pharmacokinetic parameter - time of the last point with quantifiable concentration (tlast) and terminal elimination half-life (t1/2z)
Measured: Up to D113 after inclusion
Assessment of pharmacokinetic parameter - lowest concentration of drug before the next dose (Ctrough)
Measured: Up to D113 after inclusion
Assessment of pharmacokinetic parameter - apparent total body clearance (CLss/F)
Measured: Up to D113 after inclusion
Assessment of pharmacokinetic parameter - absorption-dependent apparent volume of distribution at steady state (Vss/F)
Measured: Up to D113 after inclusion
Number of participants with anti-SAR113244 antibody titers
Measured: Up to D226 after inclusion
Pharmacodynamic parameter changes
Measured: Up to D113 after inclusion
Pharmacodynamic parameters: peripheral blood B and T cells subsets
Measured: Up to D85 after inclusion
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Dec 2014 (estimated)
- Study startNov 2014
- Primary completionMar 2016
- Study completionMar 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Systemic Lupus ErythematosusStudies of the same condition, open and under way.
- More trials run by SanofiThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 21 participants (actual)
Sponsor and investigators
- Lead sponsor
- Sanofi
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Clinical Sciences & Operations, Study director, Sanofi
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02321709
- Sponsor's protocol ID
- TDR11407
- Other IDs
- 2014-001690-13, U1111-1154-6184, 2014
- Status last verified
- Apr 2016
- First submitted
- 5 Dec 2014
- Last updated
- 2 May 2016
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 2 May 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-blind, Placebo-controlled Study Of Safety, Tolerability, And Pharmacokinetics Of Repeated Ascending Subcutaneous Doses Of SAR113244 And Pharmacodynamics Of Single Dose Of SAR113244 In Male And Female Lupus Patients
- ClinicalTrials.gov ID
- NCT02321709
- Acronym / sponsor ID
- TDR11407
- Conditions
- Systemic Lupus Erythematosus
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 21 participants (actual)
- Lead sponsor
- SanofiIndustry (pharma, biotech, devices)
- Study start
- Nov 2014
- Primary completion
- Mar 2016 (actual)
- Study completion
- Mar 2016 (actual)
- First posted
- 22 Dec 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Primary Objective:
To assess the tolerability and safety of SAR113244 in male and female lupus patients after every 4 (Q4) weeks repeated ascending subcutaneous doses of SAR113244.
Secondary Objectives:
To assess in male and female lupus patients:
- The pharmacokinetics of SAR113244.
- The pharmacodynamics of SAR113244 for the following disease-related parameters:
- Safety of Estrogens in Lupus Erythematosus National Assessment - Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score, British Isles Lupus Assessment Group (BILAG) score (if applicable), BILAG-Based Composite Lupus Assessment (BICLA) (if applicable), systemic lupus erythematosus responder index (SRI) (if applicable), Lupus-quality of life (QoL) and Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue, anti-double stranded deoxyribonucleic acid antibody (anti-dsDNA Ab) and anti-nuclear antibody levels (ANA) and plasma complement levels (C3, C4), erythrocyte sedimentation (SED) rate and C-reactive protein.
- Peripheral blood B and T cells subsets.
Detailed description
The total duration of screening to end of study per subject is 20 weeks with post-study observation on Day 226 for anti-drug antibody assessment (for patients with positive anti-drug antibody at end of study only).
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| SAR113244 cohort 1 | Experimental | Drug: SAR113244, Drug: placeboTwo administrations of dosage 1 SAR113244 or placebo subcutaneous dose (Q4 weeks) |
| SAR113244 cohort 2 | Experimental | Drug: SAR113244, Drug: placeboTwo administrations of dosage 2 SAR113244 or placebo subcutaneous dose (Q4 weeks) |
| SAR113244 cohort 3 | Experimental | Drug: SAR113244, Drug: placeboTwo administrations of dosage 3 SAR113244 or placebo subcutaneous dose (Q4 weeks) |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Male or female patients, between 18 and 75 years of age, inclusive.
- Clinical diagnosis of systemic lupus erythematosus (SLE) by American College Rheumatology criteria.
- Autoantibody-posititve.
- On active and stable SLE disease.
Key exclusion criteria (8 listed)
- Pregnant and nursing.
- Have received treatment with investigational drugs in the 4 months prior to the screening or 5 half-lives of the drug, whichever is longer.
- Have received intravenous or oral cyclophosphamide within 180 days of Day 0. Severe active lupus nephritis or chronic renal insufficiency.
- Active or chronic, severe neuropsychiatric lupus.
- Acute, recent (within 4 weeks of screening), chronic or frequently recurring infection(s), except minor infection.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SAR113244Pharmaceutical form:solution for injection Route of administration: subcutaneous | Drug | SAR113244 cohort 1, SAR113244 cohort 2, SAR113244 cohort 3 |
| placeboPharmaceutical form:solution for injection Route of administration: subcutaneous | Drug | SAR113244 cohort 1, SAR113244 cohort 2, SAR113244 cohort 3 |
Primary outcome
Number of participants with adverse events and treatment-emergent adverse events
Time frame: Up to 16 weeks after inclusion
Change in physical examination, body weight, vital signs and laboratory parameters
Time frame: Up to 16 weeks after inclusion
Safety and tolerability (erythema, swelling, degree of itching, and present pain intensity at injection site by measuring diameter and qualitative assessment)
Time frame: Up to 16 weeks after inclusion
10 secondary outcomes
Assessment of pharmacokinetic parameter - maximum concentration (Cmax)
Time frame: Up to D113 after inclusion
Assessment of pharmacokinetic parameter - time of maximum concentration (Tmax)
Time frame: Up to D113 after inclusion
Assessment of pharmacokinetic parameter - area under curve 0-4 weeks (AUC0-4w)
Time frame: Up to D113 after inclusion
Assessment of pharmacokinetic parameter - time of the last point with quantifiable concentration (tlast) and terminal elimination half-life (t1/2z)
Time frame: Up to D113 after inclusion
Assessment of pharmacokinetic parameter - lowest concentration of drug before the next dose (Ctrough)
Time frame: Up to D113 after inclusion
Assessment of pharmacokinetic parameter - apparent total body clearance (CLss/F)
Time frame: Up to D113 after inclusion
Assessment of pharmacokinetic parameter - absorption-dependent apparent volume of distribution at steady state (Vss/F)
Time frame: Up to D113 after inclusion
Number of participants with anti-SAR113244 antibody titers
Time frame: Up to D226 after inclusion
Pharmacodynamic parameter changes
Time frame: Up to D113 after inclusion
Pharmacodynamic parameters: peripheral blood B and T cells subsets
Time frame: Up to D85 after inclusion
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 May 2016.
Related trials for Systemic Lupus Erythematosus
Active, not recruitingPhase 3
A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus
Lupus Erythematosus, Systemic
Active, not recruitingPhase 3
A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus
Lupus Erythematosus, Systemic
RecruitingObservational study
Deciphering the Genetic Architecture of Autoimmune Diseases
Autoimmune Diseases
RecruitingPhase 2
Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)
Lupus Nephritis
Not yet recruitingObservational study
Pain Phenotyping of Rheumatic Diseases - An Observational Study
Rheumatic Diseases, Lupus Erythematosus, Systemic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Clinical Sciences & Operations study director
Sanofi
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing SAR113244 in people with Systemic Lupus Erythematosus, run by Sanofi at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 May 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of participants with adverse events and treatment-emergent adverse events (time frame: Up to 16 weeks after inclusion). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 May 2016; AzTrials last refreshed its copy on 31 Oct 2026.